SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
137 hedge funds and large institutions have $3.23B invested in SpringWorks Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 12 closing their positions.
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
11% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 46
10% more funds holding
Funds holding: 124 → 137 (+13)
3% more capital invested
Capital invested by funds: $3.13B → $3.23B (+$103M)
0.72% more ownership
Funds ownership: 88.96% → 89.68% (+0.72%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$52.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$38.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.4M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$24.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$114M |
| 2 |
O
OrbiMed
New York
|
-$95.5M |
| 3 |
DM
Deerfield Management
New York
|
-$69.3M |
| 4 |
Goldman Sachs
New York
|
-$16.1M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$11.3M |
SWTX Hedge Fund Activity: Q1 2021 in Review
137 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2021, worth a combined $3.23B — up 3.3% from $3.13B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SWTX positions and 12 closed out — a net gain of 13 holders — while 51 added to existing stakes and 46 trimmed.
The largest buyer was Vanguard Group, adding an estimated $95.8M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $114M.
- 137 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2021, up from 124 in Q4 2020.
- Funds reported $3.23B of SpringWorks Therapeutics stock for Q1 2021, up 3.3% quarter-over-quarter.
- 25 funds opened new SpringWorks Therapeutics positions in Q1 2021 and 12 closed out, a net change of +13 holders.
- The largest SpringWorks Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $95.8M added.
- The largest SpringWorks Therapeutics seller in Q1 2021 was Bain Capital Life Sciences Investors, an estimated $114M sold.
Based on aggregated 13F filings for Q1 2021.